Rapid determination of the pharmacokinetics and metabolic fate of gefitinib in the mouse using a combination of UPLC/MS/MS, UPLC/QToF/MS, and ion mobility (IM)-enabled UPLC/QToF/MS.

Molloy, Billy J; King, Adam; Mullin, Lauren G; Gethings, Lee A; Riley, Robert; Plumb, Robert S; Wilson, Ian D

Molloy, Billy J; King, Adam; Mullin, Lauren G; Gethings, Lee A; Riley, Robert; Plumb, Robert S; Wilson, Ian D.

Affiliation

Molloy BJ; Waters Corporation, Wilmslow, UK.
King A; Waters Corporation, Wilmslow, UK.
Mullin LG; Waters Corporation, Wilmslow, UK.
Gethings LA; Waters Corporation, Wilmslow, UK.
Riley R; Evotec (UK), Ltd., Abingdon, UK.
Plumb RS; Waters Corporation, Milford, MA, USA.
Wilson ID; Computational and Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.

Xenobiotica ; 51(4): 434-446, 2021 Apr.

Article in En | MEDLINE | ID: mdl-33280466

Subject(s)

Tandem Mass Spectrometry; Animals; Chromatography, High Pressure Liquid; Chromatography, Liquid; Gefitinib; Male; Mice; Mice, Inbred C57BL

Key words

Gefitinib; ion mobility; metabolite profiling; novel conjugates; pharmacokinetics

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tandem Mass Spectrometry Type of study: Prognostic_studies Limits: Animals Language: En Journal: Xenobiotica Year: 2021 Type: Article Affiliation country: United kingdom

Fulltext

XML

PubMed Links

Search on Google